Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bimoclomol derivative with improved pharmacological profile identified at Biorex

Oct. 18, 2000

Newest TZD approved in Europe for type 2 diabetes

Oct. 18, 2000

Glucophage XR: once-daily type 2 diabetes drug approved by FDA

Oct. 18, 2000

Enzyme replacement therapy for MPS VI proceeds to phase I/II

Oct. 17, 2000

Aventis presents several related series of anorectic compounds

Oct. 17, 2000

New agents for diabetes and related conditions emerge from joint research conducted at Japanese labs

Oct. 17, 2000

Extended-release Lescol XL cleared by FDA for cholesterol reduction

Oct. 17, 2000

NF-kappaB implicated in mechanism underlying cachexia

Oct. 17, 2000

New PGF analogues and their use in osteoporosis and glaucoma

Oct. 16, 2000

Estrogenic agents designed by AHP for use in bone and cardiovascular disorders

Oct. 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...